Fulcrum Therapeutics Inc FULC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
12.65quote price arrow down-0.22 (-1.71%)
Volume
9,056
Close
12.87quote price arrow up+0.30 (+2.39%)
Volume
471,496
52 week range
3.21 - 24.79
Loading...
  • Open12.66
  • Day High12.89
  • Day Low12.40
  • Prev Close12.57
  • 52 Week High24.79
  • 52 Week High Date04/05/22
  • 52 Week Low3.21
  • 52 Week Low Date06/10/22

Key Stats

  • Market Cap793.632M
  • Shares Out61.67M
  • 10 Day Average Volume1.13M
  • Dividend-
  • Dividend Yield-
  • Beta2.06
  • YTD % Change76.79

KEY STATS

  • Open12.66
  • Day High12.89
  • Day Low12.40
  • Prev Close12.57
  • 52 Week High24.79
  • 52 Week High Date04/05/22
  • 52 Week Low3.21
  • 52 Week Low Date06/10/22
  • Market Cap793.632M
  • Shares Out61.67M
  • 10 Day Average Volume1.13M
  • Dividend-
  • Dividend Yield-
  • Beta2.06
  • YTD % Change76.79

RATIOS/PROFITABILITY

  • EPS (TTM)-2.56
  • P/E (TTM)-5.02
  • Fwd P/E (NTM)-6.33
  • EBITDA (TTM)-105.214M
  • ROE (TTM)-47.44%
  • Revenue (TTM)10.715M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,000.65%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/01/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fulcrum Therapeutics Inc

 

Profile

MORE
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood...
Kate Haviland
Independent Chairman of the Board
Robert Gould Ph.D.
Interim President, Chief Executive Officer, Principal Executive Officer, Director
Mel Hayes
Chief Operating Officer
Esther Rajavelu
Chief Financial Officer
Curtis Oltmans J.D.
General Counsel
Address
26 Landsdowne St
Cambridge, MA
02139-4216
United States

Top Peers

SYMBOLLASTCHG%CHG
MCRB
Seres Therapeutics Inc
5.53+0.02+0.36%
MRSN
Mersana Therapeutics Inc
6.67+0.20+3.09%
FDMT
4D Molecular Therapeutics Inc
21.26+1.03+5.09%
ALLK
Allakos Inc
7.37+0.20+2.79%
VKTX
Viking Therapeutics Inc
8.57+0.17+2.02%